Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aligos Therapeutics (ALGS) Accounts Payables (2021 - 2025)

Historic Accounts Payables for Aligos Therapeutics (ALGS) over the last 5 years, with Q3 2025 value amounting to $4.7 million.

  • Aligos Therapeutics' Accounts Payables rose 6974.45% to $4.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.7 million, marking a year-over-year increase of 6974.45%. This contributed to the annual value of $2.6 million for FY2024, which is 214.54% up from last year.
  • According to the latest figures from Q3 2025, Aligos Therapeutics' Accounts Payables is $4.7 million, which was up 6974.45% from $3.9 million recorded in Q2 2025.
  • In the past 5 years, Aligos Therapeutics' Accounts Payables ranged from a high of $6.8 million in Q2 2024 and a low of $1.6 million during Q2 2021
  • Over the past 5 years, Aligos Therapeutics' median Accounts Payables value was $2.9 million (recorded in 2022), while the average stood at $3.4 million.
  • Its Accounts Payables has fluctuated over the past 5 years, first plummeted by 4686.51% in 2023, then surged by 11039.8% in 2024.
  • Over the past 5 years, Aligos Therapeutics' Accounts Payables (Quarter) stood at $3.0 million in 2021, then skyrocketed by 57.11% to $4.7 million in 2022, then tumbled by 46.87% to $2.5 million in 2023, then increased by 2.15% to $2.6 million in 2024, then soared by 80.9% to $4.7 million in 2025.
  • Its Accounts Payables was $4.7 million in Q3 2025, compared to $3.9 million in Q2 2025 and $4.5 million in Q1 2025.